Fig. 1 · Structure

Documents & Downloads

Fisetin (Fustel)

Cat. No. A10388 CAS 528-48-3
Fisetin is a flavonol, a structurally distinct chemical substance that belongs to the flavonoid group of polyphenols. It can be found in many plants, where it serves as a colouring agent. Possible anti-aging, anti-inflammatory, anti-cancer, and anti-viral properties of fisetin are under active scientific investigation.

In Stock

Publications for Fisetin

3 publications citing this product

  1. Bih-Cheng Chen, .et al. , Phytomedicine, 2019, Apr; 57:1-8 PMID: 30668312
  2. Jeng LB, .et al. , J Cell Physiol, 2018, Sep;233(9):7134-7142 PMID: 29574877
  3. Kuan-Ho Lin, .et al. , Journal of Functional Foods, 2018, 52: 212-218

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Fisetin inhibited cell-free mTOR and p70S6K activity, with reported IC50 values of 6.71E-06 M and 5.10E-06 M, respectively. The same assay reported an AKT1 IC50 of 1.44E-05 M. These values are assay-specific and do not establish broad kinase selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Sirtuin

Cellular Effect

Cell Line Activity Value Description Reference
BV-2 IC50 13.5 μM Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS addition and measured after 24 hrs by Griess assay [PMID: 28923363]
BV-2 IC50 73.02 μM Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay [PMID: 28911817]
CWR22R IC50 25.9 μM Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer [PMID: 22789812]
DU-145 IC50 > 50 μM Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay [PMID: 30165345]
DU-145 IC50 > 50 μM Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay [PMID: 28760528]
H9 EC50 122 μM Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay [PMID: 8158164]
H9 IC50 157 μM Cytotoxicity against human H9 cells after 3 days [PMID: 8158164]
HepG2 IC50 > 400 μM Cytotoxicity against human HepG2 cells by MTT assay [PMID: 21726077]
HT-22 EC50 2.8 μM Neuroprotective effect against iodoacetic acid-induced ischemia in mouse HT22 cells treated simultaneously with iodoacetic acid for 2 hrs followed by incubation in fresh medium containing drug alone for 20 hrs measured after 4 hrs by MTT assay [PMID: 19537799]
HT-22 EC50 3 μM Neuroprotective activity in mouse HT22 cells assessed as reduction in IAA-induced ischemia after 24 hrs by MTT assay [PMID: 22192055]
Huh-7 CC50 > 50 μM Cytotoxicity against human Huh7.5.1 cells by MTT assay [PMID: 22445328]
L6 IC50 > 30 μg/mL Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method 10.1039/C5MD00481K
L6 IC50 38.5 μg/mL Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis 10.1039/C5MD00481K
LNCaP IC50 34.1 μM Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay [PMID: 30165345]
LNCaP IC50 34.1 μM Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay [PMID: 28760528]
MCF-10A IC50 2.44 μM Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay [PMID: 30165345]
Monocyte IC50 3.7 μM Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs [PMID: 8882428]
PC-3 IC50 > 50 μM Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay [PMID: 30165345]
PC-3 IC50 > 50 μM Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay [PMID: 28760528]
PWR-1E IC50 5.39 μM Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay [PMID: 30165345]

20 records · Scroll to view more

Fisetin (Fustel) Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of Fisetin (Fustel) from 5 published references. In vitro models include cell-free mTOR, mTOR + FKBP12, p70S6K and AKT1 kinase assays; androgen-independent, PTEN-negative human PC3 prostate cancer cells.

Fisetin (Fustel) In Vitro Studies

In PTEN-negative PC3 prostate cancer cells, 40–120 μM fisetin for 48 h reduced recovered mTOR activity and cellular phospho-Akt (S473). ATP levels also declined, limiting interpretation of these responses as selective pathway inhibition. [2]

In etoposide-treated IMR90 fibroblasts, 48 h fisetin exposure reduced viable SA-β-gal-positive cell counts at 7.5 and 15 μM relative to DMSO controls. This marker-based result alone does not establish selective killing of senescent cells. [3]

Cell-free kinase activity profiling

Biochemical assay · Cell-free mTOR, mTOR + FKBP12, p70S6K and AKT1 kinase assays [1]

Fisetin inhibited the four assayed kinase conditions. The reported IC50 values describe this radiometric assay and are not treatment doses or a kinome-wide selectivity profile.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mTOR catalytic activity without FKBP12IC50 6.71E-06 M[1]
mTOR catalytic activity with FKBP12IC50 6.05E-06 M[1]
p70S6K catalytic activityIC50 5.10E-06 M[1]
AKT1 catalytic activityIC50 1.44E-05 M[1]

Literature-Reported Treatment Conditions

Treatment concentration
10-dose IC50 series, 3-fold serial dilution starting at 100 μM fisetin
Exposure duration
2 h at room temperature
Method
Radiometric kinase activity assay at Reaction Biology Corporation; 30 μM ATP; phosphorylation products captured on P81 filters.
Vehicle
DMSO; reaction buffer contains 1% DMSO
Co-treatment
mTOR tested with and without FKBP12. Rapamycin and staurosporine tested separately as reference inhibitors.
Reported limits
Independent replicate number and uncertainty for fitted IC50 values are not specified in the acquired kinase-activity description.
Methods and source locations

Compound reported in the paper: Fisetin

Published fisetin experiments support compound-level research context; no validation of SKU A10388 or any Adooq lot.

Materials; Kinase activity assays; Results, kinase-activity subsection; Figure 8A–E

mTOR catalytic activity without FKBP12: 32P-ATP radiometric kinase activity, normalized to DMSO control — Figure 8A–B; Kinase activity assays

mTOR catalytic activity with FKBP12: 32P-ATP radiometric kinase activity, normalized to DMSO control — Figure 8A,C; Kinase activity assays

p70S6K catalytic activity: 32P-ATP radiometric kinase activity, normalized to DMSO control — Figure 8A,D; Kinase activity assays

AKT1 catalytic activity: 32P-ATP radiometric kinase activity, normalized to DMSO control — Figure 8A,E; Kinase activity assays

mTOR/Akt pathway response in PC3 cells

Cell-based study · Androgen-independent, PTEN-negative human PC3 prostate cancer cells [2]

A 48 h exposure to fisetin reduced mTOR activity recovered from treated cells and phospho-Akt (S473). Cellular ATP also decreased. These cellular responses do not establish selective, direct enzyme inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Activity of mTOR immunoprecipitated from fisetin-treated cellsInhibition versus control 6%, 11% and 25% at 40, 80 and 120 μM, respectively[2]
Cellular phospho-Akt (S473) levelRelative level 59%, 34% and 19% at 40, 80 and 120 μM, respectively[2]
Cellular ATP levelDecrease versus control 38%, 78% and 87% at 40, 80 and 120 μM, respectively[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 40, 80 and 120 μM
Exposure duration
48 h
Method
Cell exposure followed by immunoprecipitated mTOR activity assay, phospho-Akt ELISA and cellular ATP assay.
Reported limits
The solvent and solvent fraction for the adopted Figures 1–2 exposure are not explicitly established in the read assay text; DMSO in the separate colony assay is not transferred here. Figures identify a 0 μM control.
Methods and source locations

Compound reported in the paper: Fisetin

Published fisetin experiments support compound-level research context; no validation of SKU A10388 or any Adooq lot.

Reagents and cell culture; mTOR kinase assay; Phospho-Akt ELISA; Measurement of ATP; Results for Figures 1D and 2C,E; Figures 1–2 captions

Activity of mTOR immunoprecipitated from fisetin-treated cells: K-LISA mTOR assay using S6K70 substrate; mean ± SEM, three independent experiments (caption) — Results, first subsection; Figure 1D and caption; mTOR kinase assay

Cellular phospho-Akt (S473) level: PathScan phospho-Akt (S473) ELISA; caption describes representative results of three independent experiments, mean ± SEM — Results, mTORC1/2 and Akt subsection; Figure 2C and caption; Phospho-Akt ELISA

Cellular ATP level: ATP bioluminescence assay; mean ± SEM, three independent experiments (caption) — Results, TSC2/Akt/AMPK subsection; Figure 2E and caption; Measurement of ATP

Senescence-associated cell counts in IMR90 fibroblasts

Cell-based study · Human IMR90 fibroblasts after etoposide-induced senescence [3]

Fisetin reduced the relative number of viable SA-β-gal-positive cells at 7.5 and 15 μM compared with DMSO controls. Total viable-cell counts were measured in parallel. This assay does not by itself distinguish senolysis from a change in senescence-marker expression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Viable SA-β-gal-positive IMR90 cells relative to vehicle controlQualitative reduction Lower at 7.5 μM (**p < .01) and 15 μM (****p < .0001)[3]

Literature-Reported Treatment Conditions

Treatment concentration
1, 3.75, 7.5 and 15 μM (Figure 1C); vehicle control
Exposure duration
48 h fisetin exposure
Method
IMR90 cells received 20 μM etoposide for 24 h; two days after its removal, approximately 70% were SA-β-gal positive. C12FDG imaging quantified SA-β-gal-positive cells and Hoechst imaging total viable cells.
Vehicle
DMSO; fraction not specified
Co-treatment
Sequential etoposide induction followed by fisetin; no concurrent etoposide combination claim.
Reported limits
Number of independent biological replicates for IMR90 is not clearly specified. Caption/methods refer to duplicate samples and 3–5 fields per well; Figure 1C wording states mean ± SD and the shared caption ends with mean ± SEM. No numerical error estimates adopted.
Methods and source locations

Compound reported in the paper: Fisetin

Published fisetin experiments support compound-level research context; no validation of SKU A10388 or any Adooq lot.

Materials and methods 2.1 and 2.4; Results first paragraph; Figure 1C and caption

Viable SA-β-gal-positive IMR90 cells relative to vehicle control: C12FDG fluorescence imaging; total viable cells measured in parallel; two-tailed unpaired Student’s t-test (caption) — Figure 1C and shared caption; Materials and methods 2.4

Fisetin (Fustel) In Vivo Studies

In a three-site UM-HET3 mouse study, dietary fisetin at a target 600 ppm starting at 20 months did not significantly alter lifespan in either sex. Both continuous feeding and repeated 3-day-on/11-day-off feeding were tested. Plasma exposure could not be established reliably, so the finding is bounded to the tested diets, schedules and mouse stock. [4]

A study explicitly reporting Adooq A10388 tested oral fisetin in nude-mouse colorectal xenografts at 400 or 800 mg/kg/day for four weeks. Although lower tumor-growth readouts were described, the Results state that differences among groups were not statistically significant. The experiment therefore provides limited support for antitumor efficacy. [5]

Late-life fisetin diets did not significantly alter UM-HET3 survival

Animal study · Genetically heterogeneous UM-HET3 mice of both sexes, tested at JAX, UM and UT [4]

Neither continuous nor cyclic dietary fisetin significantly changed lifespan at the tested dose and schedules. The negative result limits generalization of lifespan-extension claims across mouse stocks and administration conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Male survival: continuous and cyclic fisetin versus controlMedian age; site-stratified log-rank p Control: 750 days (n = 292); continuous: 715 days (n = 142), p = 0.85; cyclic: 799 days (n = 150), p = 0.54[4]
Female survival: continuous and cyclic fisetin versus controlMedian age; site-stratified log-rank p Control: 876 days (n = 286); continuous: 883 days (n = 144), p = 0.37; cyclic: 871 days (n = 134), p = 0.75[4]

Conditions shared by the study groups

Route
Oral dietary administration
Treatment course
Started at 20 months of age; lifespan follow-up
Vehicle
LabDiet 5LG6-based chow
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Continuous fisetin
600 ppm target in diet
Cont_18 mice fed the same base diet without test agent; males n = 292, females n = 286 (Table 1)No significant lifespan change in either sex: males p = 0.85, females p = 0.37.[4]
Cyclic fisetin
600 ppm target during on-diet periods
Cont_18 mice fed the same base diet without test agent; males n = 292, females n = 286 (Table 1)No significant lifespan change in either sex: males p = 0.54, females p = 0.75.[4]
Continuous fisetin
Model: UM-HET3 male and female mice; pooled across three testing sites
Frequency: Continuously
Reported limits: Fisetin plasma measurements were unreliable; no PK study was performed. Dietary ppm is not a measured mg/kg body-weight dose.
Cyclic fisetin
Model: UM-HET3 male and female mice; pooled across three testing sites
Frequency: Repeated 3 days on, 11 days off
Reported limits: Fisetin plasma measurements were unreliable; no PK study was performed. Dietary ppm is not a measured mg/kg body-weight dose.
Methods and source locations

Compound reported in the paper: Fisetin

Published fisetin experiments support compound-level research context; no validation of SKU A10388 or any Adooq lot.

Table 1 and footnotes; Figure 3A–B; Results and Discussion, fisetin; Experimental procedures, mouse production, removals, diets, cohort 2018 and statistics

Male survival: continuous and cyclic fisetin versus control: Lifespan follow-up; Table 1 pooled across sites; n = mice tested — Table 1, males, cohort 2018 Cont_18/Fis_On/Fis_Cyc; Figure 3A; Statistical methods

Female survival: continuous and cyclic fisetin versus control: Lifespan follow-up; Table 1 pooled across sites; n = mice tested — Table 1, females, cohort 2018 Cont_18/Fis_On/Fis_Cyc; Figure 3B; Statistical methods

Continuous fisetin · Table 1, cohort 2018 fisetin/control rows and footnotes; Figure 3A–B; Experimental procedures, diets and cohort 2018 fisetin

Cyclic fisetin · Table 1, cohort 2018 fisetin/control rows and footnotes; Figure 3A–B; Experimental procedures, diets and cohort 2018 fisetin

Colorectal xenograft tumor-growth result was not statistically significant

Animal study · 8-week-old male nude mice with parental LoVo, OR-LoVo or CPT11-LoVo colorectal xenografts [5]

The original Results describe lower tumor-growth readouts after fisetin but state that no significant result was found among groups, attributing this to the small animal numbers. This experiment does not establish significant antitumor efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growth over four weeks across parental and chemotherapy-resistant colorectal xenograftsStatistical interpretation reported by authors No significant result was found among groups (Results 3.4); exact p-values not supplied there.[5]

Conditions shared by the study groups

Route
Oral administration
Frequency
Daily
Treatment course
4 weeks, starting when tumors reached 5 mm (Methods 2.7)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Lower-dose fisetin
400 mg/kg/day
Vehicle-only groupAuthors report lower tumor-growth readouts but no statistically significant differences among groups; no exact bar heights extracted.[5]
Higher-dose fisetin
800 mg/kg/day
Vehicle-only groupAuthors report lower tumor-growth readouts but no statistically significant differences among groups; no exact bar heights extracted.[5]
Lower-dose fisetin
Model: Male nude mice bearing parental LoVo, oxaliplatin-resistant LoVo (OR), or irinotecan-resistant LoVo (CPT11) xenografts
Reported limits: Vehicle composition and precise allocation of the stated four animals per group across the model-by-dose design are not clearly specified. Figure 5 labels its endpoint Tumor area (mm³), whereas Results call it tumor volume.
Higher-dose fisetin
Model: Male nude mice bearing parental LoVo, oxaliplatin-resistant LoVo (OR), or irinotecan-resistant LoVo (CPT11) xenografts
Reported limits: Vehicle composition and precise allocation of the stated four animals per group across the model-by-dose design are not clearly specified. Figure 5 labels its endpoint Tumor area (mm³), whereas Results call it tumor volume.
Methods and source locations

Compound reported in the paper: Fisetin; Compound label in the paper: Adooq Bioscience cat. A10388

Reported use of Adooq A10388 in this paper; no lot-specific validation or conversion of stock solvent into the unspecified oral vehicle.

Materials and methods 2.1, 2.7–2.8; Results 3.4; Figure 5a–c and caption

Tumor growth over four weeks across parental and chemotherapy-resistant colorectal xenografts: Serial tumor-growth measurements; Figure 5a–c; Methods 2.8 specifies mean ± SE and Student’s t-test, significance p < 0.05. — Materials and methods 2.1, 2.7–2.8; Results 3.4; Figure 5a–c and caption

Lower-dose fisetin · Materials and methods 2.1, 2.7–2.8; Results 3.4; Figure 5a–c and caption

Higher-dose fisetin · Materials and methods 2.1, 2.7–2.8; Results 3.4; Figure 5a–c and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 528-48-3
Formula C15H10O6
Molecular Weight 286.2
Synonyms Viset; Fustel
SMILES
C1=CC(=C(C=C1C2=C(C(=O)C3=C(O2)C=C(C=C3)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 56 mg/mL (195.64 mM)
Water Insoluble
Ethanol 3 mg/mL (10.48 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Fisetin (Fustel) Research References

  1. [1] Syed DN, Chamcheu JC, Khan MI, et al. Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling Biochemical Pharmacology (2014). PMID: 24675012 DOI: 10.1016/j.bcp.2014.03.007 Source material
  2. [2] Suh Y, Afaq F, Khan N, et al. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells Carcinogenesis (2010). PMID: 20530556 DOI: 10.1093/carcin/bgq115 Source material
  3. [3] Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan EBioMedicine (2018). PMID: 30279143 DOI: 10.1016/j.ebiom.2018.09.015 Source material
  4. [4] Harrison DE, Strong R, Reifsnyder P, et al. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used GeroScience (2024). PMID: 38041783 DOI: 10.1007/s11357-023-01011-0 Source material
  5. [5] Jeng LB, Kumar Velmurugan B, Chen MC, et al. Fisetin mediated apoptotic cell death in parental and Oxaliplatin/irinotecan resistant colorectal cancer cells in vitro and in vivo Journal of Cellular Physiology (2018). PMID: 29574877 DOI: 10.1002/jcp.26532 Source material

Publications

3 publications citing this product

  1. Bih-Cheng Chen, .et al. , Phytomedicine, 2019, Apr; 57:1-8 PMID: 30668312
  2. Jeng LB, .et al. , J Cell Physiol, 2018, Sep;233(9):7134-7142 PMID: 29574877
  3. Kuan-Ho Lin, .et al. , Journal of Functional Foods, 2018, 52: 212-218

Added to your cart

View Cart Checkout
Loading...